Histopathologic and Metabolic Criteria for Assessment of Treatment Response in Breast Cancer.

[1]  Selin Carkaci,et al.  Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings , 2008, Breast Cancer Research and Treatment.

[2]  Michael Bader,et al.  Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  G. Hortobagyi,et al.  Chemotherapy: what progress in the last 5 years? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Mark Muzi,et al.  18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[6]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Terry L. Smith,et al.  The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Avril.  GLUT1 expression in tissue and (18)F-FDG uptake. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Robert B Livingston,et al.  Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[11]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[12]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Paul Kinahan,et al.  SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  E. Matoušková,et al.  Assessment of in vitro drug resistance of human breast cancer cells subcultured from biopsy specimens. , 2003, Anticancer research.

[15]  G. Hortobagyi,et al.  Chemotherapy‐Induced Apoptosis and Bcl‐2 Levels Correlate with Breast Cancer Response to Chemotherapy , 2003, Cancer journal.

[16]  A. Gumà,et al.  Pathologic Changes Related to CMF Primary Chemotherapy in Breast Cancer , 2002, Breast Cancer Research and Treatment.

[17]  M. Dowsett,et al.  The biology of neoadjuvant chemotherapy for breast cancer. , 2002, Endocrine-related cancer.

[18]  J. Bryant,et al.  Pathobiology of preoperative chemotherapy , 2002 .

[19]  D. Mankoff,et al.  Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. , 2002, Academic radiology.

[20]  Henry M Kuerer,et al.  Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline‐based neoadjuvant chemotherapy in patients with breast carcinoma , 2002, Cancer.

[21]  S. Jaffer,et al.  Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer * , 2002, Journal of surgical oncology.

[22]  F. Penault-Llorca,et al.  Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer , 2002, British Journal of Cancer.

[23]  Robert B Livingston,et al.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[25]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[26]  C. V. D. van de Velde,et al.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Ménard,et al.  HER2 as a Prognostic Factor in Breast Cancer , 2001, Oncology.

[28]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Welch,et al.  Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. McLaren,et al.  Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay , 2001, Breast Cancer Research and Treatment.

[31]  A. Vincent-Salomon,et al.  Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer , 2000, British Journal of Cancer.

[32]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[33]  A. Goldhirsch,et al.  Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[35]  P A Salvadori,et al.  Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. , 2000, Clinical breast cancer.

[36]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Cocconi.  Chemotherapy with and without anthracycline. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[40]  G. Hortobagyi,et al.  Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M Schwaiger,et al.  Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[43]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M Schwaiger,et al.  Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.

[46]  B. Leone,et al.  Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. , 1998, The cancer journal from Scientific American.

[47]  A. Vincent-Salomon,et al.  No significant predictive value of c‐ erbB‐2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer , 1998, International journal of cancer.

[48]  G. Giaccone,et al.  Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. , 1998, British Journal of Cancer.

[49]  K. Müller,et al.  Regressionsgrading neoadjuvant behandelter nichtkleinzelliger Lungenkarzinome , 1997, Der Pathologe.

[50]  P. V. van Diest,et al.  Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. , 1997, American journal of clinical pathology.

[51]  J. Coindre,et al.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.

[52]  N. Kapucuoglu,et al.  The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer , 1996, Histopathology.

[53]  R L Wahl,et al.  Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. , 1995, Radiology.

[54]  J. Bergh,et al.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  L. Norton,et al.  p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Kaufmann,et al.  Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie , 1994 .

[57]  C. Gillett,et al.  The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. , 1994, British Journal of Cancer.

[58]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[59]  R L Wahl,et al.  Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.

[60]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  P. Hurteloup,et al.  Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate , 1993 .

[62]  D. Barnes,et al.  Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? , 1993, Human pathology.

[63]  F. Ames,et al.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1992, Archives of surgery.

[64]  G. Hortobagyi,et al.  Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer , 1991, Cancer.

[65]  A. Luini,et al.  Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.

[66]  M. Merino,et al.  The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. , 1990, Human pathology.

[67]  J. F. Leijten,et al.  Rapid assay for thein vitro chemosensitivity testing of human breast tumours , 1989, Pharmaceutisch Weekblad.

[68]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[69]  G. Hortobagyi,et al.  Pathological assessment of response to induction chemotherapy in breast cancer. , 1986, Cancer research.

[70]  S. Aamdal,et al.  Estrogen receptors and long‐term prognosis in breast cancer , 1984, Cancer.

[71]  G. Delling,et al.  [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. , 1983, Der Pathologe.

[72]  P. Rosen,et al.  Estrogen receptor protein in breast cancer as a predictor of recurrence , 1981, Cancer.

[73]  Takashi Ishikawa,et al.  Current progress in the prediction of chemosensitivity for breast cancer , 2004, Breast cancer.

[74]  Baljit Singh,et al.  A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  J. Bryant,et al.  Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. , 2002, Cancer.

[76]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[77]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[79]  Michael J. Welch,et al.  Positron emission tomographic assessment of ”metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy , 1999, European Journal of Nuclear Medicine.

[80]  J. Sparano,et al.  Gross and histologic features of locally advanced breast cancer after neoadjuvant chemotherapy. , 1998, Anatomic pathology.

[81]  B Asselain,et al.  Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. , 1998, Anticancer research.

[82]  K. Franssila,et al.  Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. , 1997, British Journal of Cancer.

[83]  K. Schulmann,et al.  [Regression grading of neoadjuvant non-small-cell lung carcinoma treatment]. , 1997, Der Pathologe.

[84]  H. Junkermann,et al.  [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. , 1994, Geburtshilfe und Frauenheilkunde.

[85]  J. F. Leijten,et al.  Rapid assay for the in vitro chemosensitivity testing of human breast tumours. Control of assay conditions and quality assurance. , 1989, Pharmaceutisch weekblad. Scientific edition.

[86]  D. Kinne,et al.  Estrogen receptor protein of breast cancer as a predictor of recurrence , 1985, Cancer.

[87]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.